NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.